Overhauled AERS II System Will Be Overseen By Bioinformatics Board
This article was originally published in The Tan Sheet
Executive Summary
A new Bioinformatics Board will oversee FDA's program to develop an advanced Adverse Event Reporting System with the capability to analyze data and assist medical reviewers in spotting safety signals